Mario Occhipinti | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study	FRONTIERS IN ONCOLOGY	2024
Exploring Genomic Biomarkers for Pembrolizumab Response: A Real-World Approach and Patient Similarity Network Analysis Reveal DNA Response and Repair Gene Mutations as a Signature	CANCERS	2024
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis	JOURNAL FOR IMMUNOTHERAPY OF CANCER	2023
68P OncoMutational ratio on ctDNA: A potential novel biomarker in NSCLC	JOURNAL OF THORACIC ONCOLOGY	2023
Circulating immature neutrophils early detect hyperprogressive disease upon first-line PD-1/PD-L1 inhibitors in non-small cell lung cancer patients selecting best candidates for platinum-based chemotherapy and PD-1/PD-L1 inhibitors combinations	CANCER RESEARCH	2023
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines	JOURNAL OF THORACIC ONCOLOGY	2023
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: The IMMINENT study	JOURNAL OF CLINICAL ONCOLOGY	2023
Exploring the role of immunotherapy-based treatments for advanced non-small cell lung cancer with novel driver alterations	CLINICAL LUNG CANCER	2023
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials	CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY	2023
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors	LUNG CANCER	2023
2203P Uncovering prognostic transcriptomic differences in epithelioid malignant pleural mesothelioma	ANNALS OF ONCOLOGY	2023
1355P Evaluation of the role of variant allele frequency in EGFR mutated non-small cell lung cancer treated with first line osimertinib	ANNALS OF ONCOLOGY	2023
178P Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients	ANNALS OF ONCOLOGY	2023
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients	FRONTIERS IN ONCOLOGY	2023
Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease	TUMORI	2022
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation	COCHRANE LIBRARY	2022
Paraneoplastic neurological syndromes in patients affected by SCLC: a case series	TUMORI	2022
Immunotherapy and chemo-immunotherapy for non–small cell lung cancer with novel actionable oncogenic driver alterations.	JOURNAL OF CLINICAL ONCOLOGY	2022
Abstract 2380: The effect of metabolic alterations on chemo-immunotherapy response in non-small-cell lung cancer model	CANCER RESEARCH	2022
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy	FUTURE ONCOLOGY	2022